Skip to main content

MARSHALL WACE, LLP

Position in IBRX — ImmunityBio, Inc.

CIK 1318757 LONDON, X0

Position in IBRX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$3,394,313
+$2,803,533 QoQ
Shares Held
387,700
+403.3% QoQ
Ownership
0.037%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#58
of 403 holders
Holding Since
Dec 2021
9 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in IBRX Over Time

Shares Held

Position Value (USD)

Derivatives in IBRX

reported options exposure · as of Jun 30, 2026
CallValue
$164,593
CallShares
18,800
PutValue
$308,175
PutShares
35,200

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,014,740,742 across 267 Biotechnology names. IBRX ranks #115 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in IBRX

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $164,593 18,800
2026-06-30 $308,175 35,200
2026-06-30 $3,394,313 387,700
2026-03-31 $590,780 77,025
2026-03-31 $1,158,170 151,000
2026-03-31 $98,176 12,800
2025-09-30 $626,842 254,814
2024-12-31 $615,195 240,311
2023-03-31 $426,682 234,441
2022-12-31 $300,691 59,308
2022-09-30 $256,402 51,590
2022-03-31 $859,911 153,282
2021-12-31 $1,480,595 243,519